Find Gilteritinib Fumarate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Gilteritinib hemifumarate, Asp-2215 hemifumarate, 1254053-84-3, Gilteritinib fumarate [usan], Asp2215 hemifumarate, 5rzz0z1gjt
Molecular Formula
C62H92N16O10
Molecular Weight
1221.5  g/mol
InChI Key
UJOUWHLYTQFUCU-WXXKFALUSA-N
FDA UNII
5RZZ0Z1GJT

Gilteritinib Fumarate
Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.
1 2D Structure

Gilteritinib Fumarate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(E)-but-2-enedioic acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
2.1.2 InChI
InChI=1S/2C29H44N8O3.C4H4O4/c2*1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36;5-3(6)1-2-4(7)8/h2*5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34);1-2H,(H,5,6)(H,7,8)/b;;2-1+
2.1.3 InChI Key
UJOUWHLYTQFUCU-WXXKFALUSA-N
2.1.4 Canonical SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=CC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5.C(=C/C(=O)O)\C(=O)O
2.2 Other Identifiers
2.2.1 UNII
5RZZ0Z1GJT
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Gilteritinib Hemifumarate

2. Asp-2215 Hemifumarate

3. 1254053-84-3

4. Gilteritinib Fumarate [usan]

5. Asp2215 Hemifumarate

6. 5rzz0z1gjt

7. 1254053-84-3 (hemifumarate)

8. 2-pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2h-pyran-4-yl)amino)-, (2e)-2-butenedioate (2:1)

9. 2-pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[(tetrahydro-2h-pyran-4-yl)amino]-, (2e)-2-butenedioate (2:1)

10. 6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2h-pyran-4-yl)amino)pyrazine-2-carboxamide Hemifumarate

11. Unii-5rzz0z1gjt

12. Xospata (tn)

13. (e)-but-2-enedioic Acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide

14. Chembl3301603

15. Schembl21819929

16. Dtxsid001027950

17. Gilteritinib Fumarate (jan/usan)

18. Gilteritinib Fumarate [jan]

19. Gilteritinib Fumarate [who-dd]

20. Gilteritinib Fumarate [orange Book]

21. D10800

22. Q27262795

2.4 Create Date
2014-08-25
3 Chemical and Physical Properties
Molecular Weight 1221.5 g/mol
Molecular Formula C62H92N16O10
Hydrogen Bond Donor Count8
Hydrogen Bond Acceptor Count24
Rotatable Bond Count20
Exact Mass1220.71823320 g/mol
Monoisotopic Mass1220.71823320 g/mol
Topological Polar Surface Area317 Ų
Heavy Atom Count88
Formal Charge0
Complexity904
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Indication

Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EX13


USDMF

read-more
read-moreread-more

01

Coatings Trends
Not Confirmed

01

Coatings Trends
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-06-23

Pay. Date : 2022-06-10

DMF Number : 36745

Submission : 2022-01-31

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Gilteritinib Fumarate IH

Date of Issue : 2022-09-02

Valid Till : 2025-05-05

Written Confirmation Number : WC-0349

Address of the Firm : Unit-II, Sy. No. 50, Kardanur (Village), Patancheru (Mandai), Sangareddy Distric...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Gilteritinib fumarate

Registrant Name : Pharmapia Co., Ltd.

Registration Date : 2025-03-31

Registration Number : 20250331-211-J-1804

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : (Unit-ll) Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), S...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

GILTERITINIB FUMARATE

NDC Package Code : 54893-0120

Start Marketing Date : 2022-01-31

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Polpharma

Poland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPolpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Flag Poland
Digital Content Digital Content

Gilteritinib Fumarate

About the Company : Polpharma API, part of a leading Polish pharmaceutical group, has over 70 years of experience in process development and cGMP manufacturing. We offer end-to-end solutions, from API...

Polpharma API, part of a leading Polish pharmaceutical group, has over 70 years of experience in process development and cGMP manufacturing. We offer end-to-end solutions, from API development to scale-up, at our FDA-approved plant in Central Europe. Our expert team provides high-quality, tailor-made services for small molecule API clinical candidates, with strong regulatory support and world-class facilities. Trusted by global partners, we specialize in complex chemical processes and deliver exceptional customer experiences. Polpharma API – Your reliable European CDMO partner.
Polpharma CB

02

Arevipharma

Germany
Coatings Trends
Not Confirmed
arrow

Arevipharma

Germany
arrow
Coatings Trends
Not Confirmed

Gilteritinib Fumarate

About the Company : Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based...

Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based pharmaceutical companies on five continents. Our business partners recognise us as a competent, reliable and efficient company that is distinguished by individual service and an innovative character. The company’s 140 year history is based on the knowledge, skills, commitment and loyalty of its employees. Arevipharma also feels committed to its owners and investors. Due to the consistent expansion of new technologies,
blank

03

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Gilteritinib Fumarate

About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients and their intermediates, electronic chemical materials and intermediates, large-scale production, sales and services, and provide customized synthetic services according to customer requirements. Sjar-Tech locates in Beijing Economic and Technological Development Zone, has its own R&D and development laboratory. Sjar-Tech has set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience.
blank

04

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Gilteritinib

About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...

Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, catering to both export and import markets. The company consists of two primary business departments: the Professional Sourcing/Product Team and the Quality Team. Backed by experienced partners, Longshine has evolved into a trustworthy supplier of high-quality products and received ISO9001:2008 certification in 2017.
blank

05

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Gilteritinib Fumarate

About the Company : Hope Chem is dedicated to manufacturing, marketing, and CMO service of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals since the year 2010. Current...

Hope Chem is dedicated to manufacturing, marketing, and CMO service of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals since the year 2010. Currently, they have exclusive partnerships with multiple, state-of-the-art and GMP-compliant manufacturers in China and abroad to service our esteemed partners for competitive, long-term & stable supplies. The main products are APIs and intermediates of antiviral drug substances and anti-inflammatory, analgesic, and non-steroidal pharmaceuticals.
blank

06

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Gilteritinib Fumarate

About the Company : Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. The company specializes in the R&D, production, and...

Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. The company specializes in the R&D, production, and sales of generic APIs and intermediates, focusing on high-value APIs such as Dapoxetine Hydrochloride, Tadalafil, and others to meet diverse market needs. Located in the Yuechi Economic Development Zone, Sichuan Province, the manufacturing site spans 100 acres within a provincial-level chemical industry park. Phase one includes 4 independent production lines and a Class D GMP workshop, equipped with 500L to 5000L multifunctional reactors.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684780200,"product":"MSN PHARMACEUTICAL PRODUCT NAMEAS PER ATTACHED INVOICE NO 1905235046 GILTERITINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"54450","totalValueFC":"2637.2","currency":"USD","unitRateINR":4340000,"date":"23-May-2023","totalValueINR":"217000","totalValueInUsd":"2637.2","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693161000,"product":"GILTERITINIB FUMARATE","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"NA","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.40","actualQuantity":"0.4","unit":"KGS","unitRateFc":"59732.4","totalValueFC":"23709.4","currency":"USD","unitRateINR":4909999.9924999997,"date":"28-Aug-2023","totalValueINR":"1963999.997","totalValueInUsd":"23709.4","indian_port":"HYDERABAD ICD","hs_no":"29333990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"SOUTH KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728498600,"product":"GILTERITINIB N MSN PW UD AL (3 G) B\/N- B745284","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"SANDOZ PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"PIRC KARMEN SCIENTIST PD","customerCountry":"SLOVENIA","quantity":"0.00","actualQuantity":"0.003","unit":"KGS","unitRateFc":"50000","totalValueFC":"148.4","currency":"USD","unitRateINR":4155146.666666667,"date":"10-Oct-2024","totalValueINR":"12465.44","totalValueInUsd":"148.4","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"4741436","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"SANDOZ HOUSE, MUMBAI ,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745519400,"product":"GILTERITINIB FUMARATE.","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SAO PAULO - CONGONHA","customer":"EUROFARMA LABORATRIOS S A","customerCountry":"BRAZIL","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"43000","totalValueFC":"170188","currency":"USD","unitRateINR":3642100,"date":"25-Apr-2025","totalValueINR":"14568400","totalValueInUsd":"170188","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"1277123","productDescription":"API","marketType":"","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753900200,"product":"GILTERITINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM PRATTELN BONDED","customerCountry":"SWITZERLAND","quantity":"0.60","actualQuantity":"600","unit":"GMS","unitRateFc":"49.5","totalValueFC":"29249.3","currency":"USD","unitRateINR":4195.6149999999998,"date":"31-Jul-2025","totalValueINR":"2517369","totalValueInUsd":"29249.3","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4057485","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
23-May-2023
31-Jul-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
Coatings Trends
Not Confirmed
arrow
Coatings Trends
Not Confirmed

Company : Astellas Pharma

Gilteritinib Fumarate

Drug Cost (USD) : 89,759,419

Year : 2023

Prescribers : 924

Prescriptions : 3881

blank

02

arrow
Coatings Trends
Not Confirmed
arrow
Coatings Trends
Not Confirmed

Company : Astellas Pharma

Gilteritinib Fumarate

Drug Cost (USD) : 75,577,732

Year : 2022

Prescribers : 789

Prescriptions : 3247

blank

03

arrow
Coatings Trends
Not Confirmed
arrow
Coatings Trends
Not Confirmed

Company : Astellas Pharma

Gilteritinib Fumarate

Drug Cost (USD) : 70,195,773

Year : 2021

Prescribers : 726

Prescriptions : 3090

blank

04

arrow
Coatings Trends
Not Confirmed
arrow
Coatings Trends
Not Confirmed

Company : Astellas Pharma

Gilteritinib Fumarate

Drug Cost (USD) : 58,718,494

Year : 2020

Prescribers : 654

Prescriptions : 2593

blank

05

arrow
Coatings Trends
Not Confirmed
arrow
Coatings Trends
Not Confirmed

Company : Astellas Pharma

Gilteritinib Fumarate

Drug Cost (USD) : 33,172,101

Year : 2019

Prescribers : 427

Prescriptions : 1490

blank

06

arrow
Coatings Trends
Not Confirmed
arrow
Coatings Trends
Not Confirmed

Company : Astellas Pharma

Gilteritinib Fumarate

Drug Cost (USD) : 775,798

Year : 2018

Prescribers : 32

Prescriptions : 33

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1254053-84-3 / Gilteritinib Fumarate API manufacturers, exporters & distributors?

Gilteritinib Fumarate manufacturers, exporters & distributors 1

72

PharmaCompass offers a list of Gilteritinib Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gilteritinib Fumarate manufacturer or Gilteritinib Fumarate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gilteritinib Fumarate manufacturer or Gilteritinib Fumarate supplier.

PharmaCompass also assists you with knowing the Gilteritinib Fumarate API Price utilized in the formulation of products. Gilteritinib Fumarate API Price is not always fixed or binding as the Gilteritinib Fumarate Price is obtained through a variety of data sources. The Gilteritinib Fumarate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Gilteritinib Fumarate

Synonyms

Gilteritinib hemifumarate, Asp-2215 hemifumarate, 1254053-84-3, Gilteritinib fumarate [usan], Asp2215 hemifumarate, 5rzz0z1gjt

Cas Number

1254053-84-3

Unique Ingredient Identifier (UNII)

5RZZ0Z1GJT

About Gilteritinib Fumarate

Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.

Gilteritinib Manufacturers

A Gilteritinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gilteritinib, including repackagers and relabelers. The FDA regulates Gilteritinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gilteritinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Gilteritinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Gilteritinib Suppliers

A Gilteritinib supplier is an individual or a company that provides Gilteritinib active pharmaceutical ingredient (API) or Gilteritinib finished formulations upon request. The Gilteritinib suppliers may include Gilteritinib API manufacturers, exporters, distributors and traders.

click here to find a list of Gilteritinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Gilteritinib USDMF

A Gilteritinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Gilteritinib active pharmaceutical ingredient (API) in detail. Different forms of Gilteritinib DMFs exist exist since differing nations have different regulations, such as Gilteritinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Gilteritinib DMF submitted to regulatory agencies in the US is known as a USDMF. Gilteritinib USDMF includes data on Gilteritinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Gilteritinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Gilteritinib suppliers with USDMF on PharmaCompass.

Gilteritinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Gilteritinib Drug Master File in Korea (Gilteritinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Gilteritinib. The MFDS reviews the Gilteritinib KDMF as part of the drug registration process and uses the information provided in the Gilteritinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Gilteritinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Gilteritinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Gilteritinib suppliers with KDMF on PharmaCompass.

Gilteritinib WC

A Gilteritinib written confirmation (Gilteritinib WC) is an official document issued by a regulatory agency to a Gilteritinib manufacturer, verifying that the manufacturing facility of a Gilteritinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Gilteritinib APIs or Gilteritinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Gilteritinib WC (written confirmation) as part of the regulatory process.

click here to find a list of Gilteritinib suppliers with Written Confirmation (WC) on PharmaCompass.

Gilteritinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Gilteritinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Gilteritinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Gilteritinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Gilteritinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Gilteritinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Gilteritinib suppliers with NDC on PharmaCompass.

Gilteritinib GMP

Gilteritinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Gilteritinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gilteritinib GMP manufacturer or Gilteritinib GMP API supplier for your needs.

Gilteritinib CoA

A Gilteritinib CoA (Certificate of Analysis) is a formal document that attests to Gilteritinib's compliance with Gilteritinib specifications and serves as a tool for batch-level quality control.

Gilteritinib CoA mostly includes findings from lab analyses of a specific batch. For each Gilteritinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Gilteritinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Gilteritinib EP), Gilteritinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gilteritinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty